Hospital
Bethesda Hospital, INC.
Bethesda Hospital, INC. was paid $23.18M by Medicaid between Jan 2018 and Dec 2024, across 244 billing codes. Its largest line is 99284, emergency room visit (serious) — 15% of everything it billed.
33Billing provider infoBETHESDA HOSPITAL, INC.
BOYNTON BEACH, FL 33435
BOYNTON BEACH, FL 33435
33aNPI1417952748assigned 06/14/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.18M
24GClaims820,550
24DCodes billed244
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#9 of 163
Median peer was paid$4.77M
This provider vs. median4.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 70,920 | $1.70M | |
| 2019 | 181,658 | $5.59M | |
| 2020 | 144,947 | $3.37M | |
| 2021 | 175,036 | $4.30M | |
| 2022 | 149,263 | $4.31M | |
| 2023 | 70,830 | $2.53M | |
| 2024incomplete | 27,896 | $1.38M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 42,013 | 35,226 | $3.46M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 13% | 26,647 | 6,610 | $2.94M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 8.5% | 26,646 | 6,666 | $1.96M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.3% | 24,621 | 22,528 | $1.92M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.0% | 23,890 | 20,655 | $1.85M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 4.6% | 13,601 | 3,848 | $1.07M |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.1% | 13,295 | 10,204 | $947K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 3.1% | 9,954 | 7,825 | $707K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 6,077 | 4,918 | $538K |
| 59025 | Fetal non-stress test | 2.3% | 11,765 | 8,529 | $525K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 9,237 | 7,197 | $488K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 3,036 | 2,628 | $427K |
232 more codes
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 4,770 | $373K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 1.6% | 6,639 | $370K |
| 36415 | Collection of venous blood by venipuncture | 1.5% | 52,443 | $344K |
| 92526 | 1.4% | 8,845 | $332K | |
| 76819 | Fetal biophysical profile; without non-stress testing | 1.3% | 10,546 | $307K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 2,599 | $287K |
| G0378 | Hospital observation service, per hour | 1.2% | 5,753 | $273K |
| J7120 | Ringers lactate infusion, up to 1000 cc | 1.1% | 6,094 | $256K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 1.0% | 12,823 | $232K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16,014 | $199K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 1,077 | $188K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,969 | $134K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,235 | $131K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,217 | $124K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,225 | $119K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,224 | $100K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 27,553 | $98K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 935 | $96K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12,286 | $84K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 13,684 | $84K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,388 | $83K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,930 | $83K |
| 80053 | Comprehensive metabolic panel | <1% | 15,976 | $72K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 41,012 | $62K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,586 | $62K |
| 0225U | <1% | 616 | $58K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,207 | $55K |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,051 | $53K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,346 | $52K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,139 | $48K |
| 82731 | <1% | 881 | $47K | |
| 81001 | <1% | 26,451 | $47K | |
| 81025 | <1% | 5,486 | $46K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,245 | $42K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,280 | $42K |
| 86850 | <1% | 6,973 | $42K | |
| 97162 | <1% | 482 | $41K | |
| 87070 | <1% | 2,995 | $39K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,032 | $37K |
| 85610 | <1% | 10,276 | $37K | |
| 85730 | <1% | 9,658 | $37K | |
| 92523 | <1% | 362 | $36K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,306 | $36K |
| C1769 | Guide wire | <1% | 1,613 | $36K |
| 76830 | Ultrasound, transvaginal | <1% | 1,430 | $35K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,922 | $35K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 888 | $29K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,958 | $28K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,830 | $27K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,356 | $27K |
| 86900 | <1% | 7,961 | $27K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,507 | $25K |
| 82948 | <1% | 1,897 | $25K | |
| 86901 | <1% | 8,011 | $25K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 942 | $23K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,778 | $23K |
| 74018 | <1% | 1,581 | $23K | |
| 85027 | <1% | 6,507 | $22K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,527 | $22K |
| 87040 | <1% | 4,518 | $20K | |
| 92610 | <1% | 313 | $18K | |
| 97166 | <1% | 131 | $18K | |
| 84484 | <1% | 7,937 | $18K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,792 | $18K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 13,963 | $18K |
| 83735 | <1% | 9,452 | $18K | |
| 87631 | <1% | 579 | $17K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 260 | $16K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 388 | $14K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,141 | $13K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,626 | $13K |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 533 | $12K |
| 82550 | <1% | 3,023 | $11K | |
| J1815 | Injection, insulin, per 5 units | <1% | 940 | $10K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 266 | $10K |
| 94664 | <1% | 3,446 | $10K | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 141 | $10K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,307 | $9K |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 280 | $9K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,920 | $9K |
| 12011 | <1% | 319 | $9K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,179 | $9K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 508 | $9K |
| 73630 | <1% | 865 | $9K | |
| 87077 | <1% | 1,951 | $9K | |
| 84100 | <1% | 2,048 | $9K | |
| 73562 | <1% | 808 | $8K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,991 | $8K |
| 97163 | <1% | 54 | $8K | |
| 80076 | <1% | 8,943 | $8K | |
| 73610 | <1% | 693 | $8K | |
| 93971 | <1% | 509 | $8K | |
| 97161 | <1% | 829 | $8K | |
| 97165 | <1% | 462 | $7K | |
| 82553 | <1% | 788 | $7K | |
| 83690 | <1% | 10,072 | $7K | |
| 76770 | <1% | 184 | $7K | |
| 87205 | <1% | 2,015 | $7K | |
| 74019 | <1% | 389 | $6K | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 193 | $6K |
| 73130 | <1% | 341 | $6K | |
| 83880 | <1% | 2,351 | $5K | |
| A4402 | Lubricant, per ounce | <1% | 78 | $5K |
| 73030 | <1% | 411 | $5K | |
| 97168 | <1% | 33 | $5K | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 76 | $5K |
| 36902 | <1% | 25 | $5K | |
| 84112 | <1% | 164 | $5K | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 181 | $5K |
| 76937 | <1% | 135 | $5K | |
| A4314 | Insertion tray with drainage bag with indwelling catheter, foley type, two-way latex with coating (teflon, silicone, silicone elastomer or hydrophilic, etc.) | <1% | 590 | $5K |
| 84702 | <1% | 5,198 | $4K | |
| 70486 | <1% | 112 | $4K | |
| 96367 | <1% | 565 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,491 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 84 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,646 | $4K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 559 | $4K |
| 84703 | <1% | 4,228 | $4K | |
| 10060 | <1% | 111 | $4K | |
| 73110 | <1% | 262 | $3K | |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 87 | $3K |
| 87632 | <1% | 630 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,998 | $3K |
| 83986 | <1% | 53 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 545 | $3K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 813 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 619 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,015 | $3K |
| 93970 | <1% | 139 | $3K | |
| 51701 | <1% | 1,304 | $3K | |
| 81003 | <1% | 2,773 | $2K | |
| 71250 | <1% | 63 | $2K | |
| 97116 | <1% | 320 | $2K | |
| 29125 | <1% | 254 | $2K | |
| 87186 | <1% | 2,146 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,073 | $2K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,082 | $2K |
| 86141 | <1% | 4,405 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 151 | $2K |
| 74022 | <1% | 115 | $2K | |
| 87807 | <1% | 3,095 | $2K | |
| 87075 | <1% | 317 | $2K | |
| 80061 | Lipid panel | <1% | 413 | $2K |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 49 | $1K |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 49 | $1K |
| 88304 | <1% | 374 | $1K | |
| 72100 | <1% | 160 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 248 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,368 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,074 | $1K |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 129 | $948.60 |
| 82150 | <1% | 1,060 | $917.64 | |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 107 | $902.43 |
| J2720 | Injection, protamine sulfate, per 10 mg | <1% | 55 | $852.43 |
| 76801 | <1% | 13 | $834.08 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 437 | $820.37 |
| 59050 | <1% | 168 | $782.67 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 24 | $779.37 |
| 96376 | <1% | 1,660 | $755.17 | |
| 90715 | <1% | 349 | $751.47 | |
| A4550 | Surgical trays | <1% | 13 | $653.59 |
| 85652 | <1% | 948 | $633.45 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 35 | $606.78 |
| 73080 | <1% | 72 | $575.42 | |
| 84132 | <1% | 75 | $537.72 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 423 | $537.26 |
| C1729 | Catheter, drainage | <1% | 216 | $431.75 |
| 97164 | <1% | 12 | $419.17 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 313 | $417.48 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 17 | $417.48 |
| 83605 | <1% | 626 | $408.63 | |
| 85379 | <1% | 1,246 | $390.67 | |
| 87045 | <1% | 29 | $358.92 | |
| 86920 | <1% | 314 | $334.21 | |
| 82607 | <1% | 121 | $312.01 | |
| 82746 | <1% | 112 | $307.23 | |
| A9270 | Non-covered item or service | <1% | 65 | $298.95 |
| 86738 | <1% | 264 | $280.36 | |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | <1% | 805 | $261.32 |
| 82270 | <1% | 15 | $235.77 | |
| 31720 | <1% | 81 | $231.97 | |
| 73502 | <1% | 15 | $224.32 | |
| 29515 | <1% | 16 | $189.00 | |
| 87802 | <1% | 15 | $176.50 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 766 | $126.55 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 258 | $103.40 |
| 12001 | <1% | 47 | $98.19 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 121 | $65.57 |
| 87210 | <1% | 92 | $65.34 | |
| 80074 | <1% | 13 | $46.85 | |
| 87340 | <1% | 27 | $36.76 | |
| 87808 | <1% | 806 | $35.17 | |
| 85384 | <1% | 1,240 | $19.79 | |
| 83615 | <1% | 867 | $16.67 | |
| 86762 | <1% | 12 | $15.82 | |
| 84550 | <1% | 825 | $12.28 | |
| 85362 | <1% | 777 | $10.89 | |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 37 | $9.28 |
| 85007 | <1% | 736 | $8.37 | |
| 82728 | <1% | 77 | $6.68 | |
| 86592 | <1% | 37 | $6.61 | |
| 84156 | <1% | 48 | $4.79 | |
| 83540 | <1% | 75 | $3.36 | |
| 85045 | <1% | 70 | $1.76 | |
| C1757 | Catheter, thrombectomy/embolectomy | 0% | 19 | $0.00 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 83 | $0.00 |
| 82805 | 0% | 28 | $0.00 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 113 | $0.00 |
| 82375 | 0% | 31 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 200 | $0.00 |
| 87899 | 0% | 52 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 207 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 102 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 56 | $0.00 |
| 85461 | 0% | 16 | $0.00 | |
| 29105 | 0% | 14 | $0.00 | |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | 0% | 12 | $0.00 |
| 29505 | 0% | 13 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 23 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 14 | $0.00 |
| 87088 | 0% | 99 | $0.00 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 0% | 21 | $0.00 |
| 83550 | 0% | 27 | $0.00 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 0% | 215 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 29 | $0.00 |
| 87046 | 0% | 30 | $0.00 | |
| 36430 | 0% | 30 | $0.00 | |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 0% | 39 | $0.00 |
| J1741 | Injection, ibuprofen, 100 mg | 0% | 34 | $0.00 |
| M0244 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency | 0% | 21 | $0.00 |
| 82575 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSMITH, JARED (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Acute Care Billing LLC | Winfield, KS | $342K |
| Jared Smith, Professional LLC | Bailey, CO | $62K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.